Bezjak, A., Dixon, P., Brundage, M., Tu, D., Palmer, M.J., Blood, P., Grafton, C., Lochrin, C., Leong, C., Mulroy, L., Smith, C., Wright, J. and Pater, J.L. (2002) Randomized Phase III Trial of Single Versus Fractionated Thoracic Radiation in the Palliation of Patients with Lung Cancer (NCIC CTG SC.15). International Journal of Radiation Oncology* Biology*Physics, 54, 719-728.
http://dx.doi.org/10.1016/S0360-3016(02)02989-9

has been cited by the following article:

• TITLE: A Clinic-Epidemilogical Study of Cases of Locally Advanced Non Small Cell Lung Cancer (NSCLC) That Received Radiotherapy at NCI Cairo in the Period from 2001-2010

  AUTHORS: Mohamed Lotayef, Azza Taher, Hanna Attia, Azza Nasr, Hisham El Hossieny, Mohammed Mahmoud, Noha Essam

  KEYWORDS: Non Small Cell Lung Cancer, Concomitant Chemo-Radiotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.6, May 16, 2014

  ABSTRACT: Purpose: This work was to study the clinic-epidemiological characteristics of patients with locally advanced NCSLC and to analyze their prognostic factors and also the results of different treatment modalities for local control and their effect on overall survival (OAS). Materials and Methods: This is a retrospective study including 121 patients with primary locally advanced NSCLC diagnosed between 2001 and 2010 at the radiotherapy department , National Cancer Institute, Cairo University, Egypt. Results: The study showed significant correlation between the tumor size 60, moderately differentiated tumors G2 and treatment outcomes; better locoregional control and better survival rates. On the opposite side poorly differentiated tumors G3, tumor size > 7 cm had the worst locoregional control and survival rates. The study also showed significant statistical correlation between treatment modality, locoregional control and survival rates. Patients who were treated by either concommitent chemo-radiotherapy or sequential chemo-radiotherapy had better local control compared to other patients who were treated by radical radiotherapy, and they also had the best survival rates among all the other treatment groups. The average 6 months OAS rates for all studied patients were 60.3% while 12 months survival rates were 38.8%. The median OAS was 7 months. Conclusions: From the present study, we concluded that concomitant chemo-radiotherapy is the treatment of choice for locally advanced non small cell lung cancer; also we concluded that better performance status and higher hemoglobin levels have better treatment outcome in these cases.